It sold its Design & Engineering business to Cadence for roughly €2.7 billion.

It spun off an entire division, Octave, and handed it to shareholders as a separately listed company.

And then, in the same stretch, it went out and bought a non-destructive testing business, Waygate Technologies, to bolt onto what was left.

That’s an unusual amount of surgery for one half-year.

The interesting part isn’t that Hexagon did it – plenty of conglomerates decide to focus. The interesting part is that the first quarter reported under the new, smaller structure came in stronger than almost anything the old, bigger structure produced in years.

That’s the kind of coincidence worth interrogating rather than just applauding.

The Short Version

Hexagon is a Swedish industrial technology company that makes the sensors, software, and positioning systems used to measure and navigate the physical world – everything from coordinate measuring machines on a factory floor to GNSS receivers that keep autonomous tractors in a straight line.

Market cap sits around SEK 250 billion (roughly €22.5 billion) after a sharp post-earnings rally.

For readers outside Sweden: this is the kind of company Stockholm produces a lot of – precision industrial technology, family-anchored ownership through Melker Schörling AB, decades of bolt-on acquisitions – but with genuinely global end markets and very little that’s parochial about the business itself.

What Hexagon Actually Sells, and to Whom

Strip away the segment names and Hexagon has three ways of making money.

Manufacturing Intelligence sells measurement hardware and software to factories – coordinate measuring machines, laser trackers, production software – to aerospace, electronics, and general manufacturing customers who need to verify that what they built matches what they designed, often to tolerances measured in microns.

Infrastructure & Geospatial sells the equivalent toolkit to construction and surveying – laser scanners, machine control systems for excavators, mapping software.

Autonomous Solutions is the newest and fastest-growing leg: GNSS positioning modules and correction services that go into mining equipment, agricultural machinery, and increasingly defense applications, through brands like NovAtel and Septentrio.

The common thread across all three is that customers aren’t buying a one-off box.

A coordinate measuring machine gets embedded into a factory’s quality control workflow; a GNSS module gets designed into another company’s product for years.

That creates real switching costs, and it’s a large part of why 26 percent of Q2 revenue was recurring – subscription software, maintenance, and consumables that don’t evaporate when a single hardware refresh cycle slows down.

The growth strategy right now is explicitly acquisitive rather than purely organic.

Waygate, announced in the quarter, pushes Hexagon into non-destructive testing – inspecting welds and castings without damaging them – which sits adjacent to existing metrology customers in aerospace and energy.

Management framed it as expanding the addressable market rather than diversifying away from it, and at roughly $630 million of 2025 revenue with a 10 percent operating margin, it’s a bolt-on, not a bet-the-company deal.

Two smaller acquisitions, Inertial Sense and ITRES Research, filled out the positioning and mapping portfolio further.

None of this is exotic.

It’s the same playbook Hexagon has run for two decades – buy adjacent capability, sell it through the same channel.

The Numbers That Actually Moved Me

Twelve percent organic growth is the headline, and it’s real – the highest Hexagon has posted in five years, and unusually broad: Autonomous Solutions grew 20 percent, Manufacturing Intelligence 13 percent, and even Infrastructure & Geospatial, which is fighting a genuinely weak European construction market, still managed 4 percent.

When your weakest segment is still growing, the story isn’t one lucky division.

But growth alone doesn’t tell you whether a restructuring worked – margin does, because margin is where operating leverage either shows up or doesn’t.

EBITAC margin excluding Robotics came in at 24.3 percent, up from 22.3 percent a year earlier.

Strip out the divested D&E business from last year’s comparison and the underlying improvement was closer to 330 basis points, of which management attributed about 230 basis points to organic growth flowing through with early benefits from its cost restructuring program, and the rest to currency.

That’s a genuinely useful split, because it tells you how much of the margin gain is structural versus a tailwind that can reverse.

Cash conversion is the number I watch most closely, because it’s the hardest one to fake.

It came in at 149 percent of EBITAC in the quarter, up from 124 percent, even while hardware sales – which typically eat working capital – were rising sharply.

Net debt fell to just 0.09x EBITDA.

Some of that improvement is mechanical, a function of the D&E and Octave proceeds flowing through the balance sheet rather than pure operating cash generation, but it leaves Hexagon with enough dry powder to keep doing bolt-ons like Waygate without stretching the balance sheet.

What the Chart Is Actually Showing

The stock jumped roughly 12 percent on report day, against a Stockholm large-cap index that barely moved.

That’s not a drift-up on relief – it’s a repricing.

Sell-side desks moved fast: SEB lifted its target to SEK 100 from 93, Citigroup to SEK 95 from 82, JP Morgan to SEK 90 from 85, all within 24 hours of the print.

What that tells me is less about where the stock goes next and more about how low expectations had drifted after a multi-year stretch of declining return on capital employed – from 13 percent in 2021 down to 10 percent in 2025.

A one-quarter rebound doesn’t erase four years of a falling trend on its own, but it’s the first data point that argues the trend has actually turned rather than just paused.

What the Market Might Be Missing – or Might Not Be

The consensus read on Hexagon right now is straightforward: the breakup worked, buy the execution.

I don’t think that’s wrong, but I think it’s under-pricing one variable – how much of the 12 percent came from tariff-related catch-up spending in manufacturing that isn’t a recurring driver.

Management acknowledged as much in its own commentary about demand patterns.

If a meaningful chunk of this quarter’s strength was customers front-loading orders ahead of anticipated tariff costs, Q3’s comparison gets harder, not easier, and a market that just re-rated the stock on the assumption of a new higher-growth baseline could find itself disappointed by a perfectly respectable but merely high-single-digit number.

The Risks I’d Actually Worry About

First, the growth durability question above – if organic growth drops back toward 6-8 percent in Q3, the stock’s one-day re-rating looks premature, not wrong, but early.

Second, Waygate integration risk: Hexagon is absorbing a $630 million acquisition into a business that just went through two other structural transactions in the same six months, and integration bandwidth is finite even at a company with Hexagon’s M&A track record.

Third, Robotics remains a cash drag with no committed timeline to profitability – €10.5 million invested in the quarter alone, explicitly excluded from the group’s own margin targets because management doesn’t think it’s fair to judge it on the same terms yet.

That’s honest framing, but it also means the market is being asked to underwrite a call option with no visible strike price.

Where I Land

I think the restructuring thesis is validated, not proven.

One quarter of 12 percent organic growth after two divestitures and one large acquisition is a genuinely strong data point, and the margin math behind it – roughly two-thirds structural, one-third currency – is more convincing than the headline number alone.

But the stock already moved to reflect that.

For the thesis to earn a higher price from here, I’d want to see three specific things: organic growth holding in mid-to-high single digits even as the tariff-related tailwind fades, EBITAC margin continuing to close the gap toward the new 24-26 percent target range management set at its April capital markets day, and Waygate integrating without a visible drag on Manufacturing Intelligence margins when it closes in H2.

This is a name for the investor who wants exposure to a genuine industrial-technology quality compounder mid-turnaround, with a controlling family shareholder and a balance sheet clean enough to keep doing accretive bolt-ons.

It’s the wrong stock if you’re looking for a re-rating catalyst that hasn’t already happened – the easy part of this story, the one-day surprise, is behind it, and what’s left is the harder job of proving Q2 wasn’t the peak.

Spotify spent the better part of two decades letting investors debate whether it could ever be genuinely profitable. That debate is now effectively over, and most of the commentary since the second-quarter print has focused on the wrong headline number.

The 300 million Premium subscriber milestone got the attention. The number that should have gotten more of it is 33.4 percent — Spotify’s gross margin in the quarter, a record, and the sixth straight quarter of expansion.

Reaching 300 million subscribers is a nice round number for a press release. Six consecutive quarters of margin expansion is a pattern, and patterns are what separate a story from a thesis.

What Spotify Actually Sells

Spotify runs a two-sided marketplace, not just a streaming app. On one side sit 777 million monthly active users, split between 300 million paying Premium subscribers and 494 million ad-supported listeners who cost the company almost nothing to serve beyond bandwidth and licensing.

On the other side sit the rights holders — record labels, podcasters, audiobook publishers — who need Spotify’s distribution and, increasingly, its marketing tools and analytics to reach an audience they couldn’t otherwise assemble on their own.

The Premium side is straightforward: subscribers pay a monthly fee across Individual, Family, Duo, and Student tiers, and Spotify keeps the difference between that fee and what it owes in royalties.

The Ad-Supported side monetizes the free tier through display, audio, and video advertising, increasingly sold through automated exchanges rather than direct sales teams — a shift that matters because programmatic buying scales without proportional headcount growth.

Together, these segments generated 4.78 billion euros in the second quarter, up 14 percent year over year.

What makes the model interesting isn’t the subscription mechanic itself — that’s Netflix’s playbook too.

It’s that Spotify doesn’t own the content it sells. Roughly 72 percent of everything streamed runs through licensing agreements with Universal Music Group, Sony Music Entertainment, and Warner Music Group, plus Merlin for independent labels.

That’s the defining structural feature of this business: Spotify controls distribution and discovery, but not the underlying product.

Every dollar of gross margin expansion has come from growing revenue faster than a royalty base Spotify can’t unilaterally renegotiate downward.

The company is now pushing into adjacent marketplace products that widen the moat a little further from pure distribution.

Audiobooks+ add-on tiers, a Reserved concert-ticket program built with Live Nation that’s already moved nearly 100,000 tickets, and AI-generated Personal Podcasts are all attempts to build revenue streams where Spotify captures more value per user without needing new licensing leverage over the majors.

The Numbers That Aren’t on the Press Release

Start with the one everyone quoted: gross margin at 33.4 percent, up 193 basis points year over year.

That’s a record, and it’s not a one-quarter fluke — margin has now expanded in Premium (34.9 percent, up 174 basis points) and Ad-Supported (19.1 percent, up 179 basis points) simultaneously, which tells you the improvement isn’t just a mix shift toward the higher-margin subscription business.

Both halves of the company are getting more efficient at the same time.

Operating income tells a similar story but with more drama: 655 million euros in the quarter, up 61 percent year over year, against an operating loss of 446 million euros for the entirety of 2023.

That’s not incremental improvement — that’s a business that crossed a structural threshold.

Then there’s the balance sheet move that got comparatively little attention: Spotify fully repaid its Exchangeable Notes — 1.3 billion euros — during the first quarter of 2026.

The company now sits in a net cash position, with roughly 10.5 billion euros in cash, short-term, and long-term investments and effectively zero financial debt.

Combine that with accelerating buybacks — 662 million dollars repurchased year-to-date through early August, up 30 percent from the same period a year ago — and you have a company that’s gone from cash-burning growth story to disciplined capital allocator in under three years.

Premium ARPU is the one number that doesn’t fit the clean narrative. It actually fell 1 percent for full-year 2025, to 4.63 euros, as currency headwinds and product mix offset price increases.

Worth watching, because ARPU softness is exactly the kind of thing that can quietly erode margin gains if it persists.

But the number I watch most closely is free cash flow on a trailing-twelve-month basis, because it strips out the noise in quarterly operating income — including the currency-linked ”Social Charges” swings the company itself flags as volatile — and shows the underlying cash generation trend without distortion.

What the Chart Isn’t Telling You About the Margin Story

The trailing-twelve-month free cash flow chart above looks almost too clean — a nearly uninterrupted climb from 209 million euros to 3.26 billion euros in under three years.

What it doesn’t show is how lumpy the underlying quarters were to get there: capital expenditures remain minimal (21 million euros in the latest quarter, under half a percent of revenue), so this isn’t a capex story.

It’s almost entirely an operating income and working capital story, which means the trend is more durable than a chart driven by one-off asset sales or tax credits would be.

The flattening between September and December 2025 — 2,917 million to 2,874 million euros — is the only real pause in an otherwise relentless line, and it lines up with typical seasonal working capital timing rather than any deterioration in the underlying business.

The Market Has Already Priced In the Easy Part

Wall Street’s read on Spotify right now is straightforward: analyst consensus leans heavily bullish, with buy ratings dominating across every source I checked

, and average price targets clustered somewhere between 585 and 620 dollars depending on which aggregator you trust — a meaningful spread on its own, worth noting.

That’s roughly 20 to 25 percent upside from current levels.

Here’s my pushback: the market isn’t wrong that the margin story is real, but a forward P/E above 30 times and an EV/EBITDA near 21 times already assumes this expansion continues for several more years without a hiccup.

Compare that to SiriusXM, trading at roughly 7.7 times EV/EBITDA — a genuinely unfair comparison given SiriusXM is a structurally shrinking satellite radio business, but it’s illustrative of just how much growth and margin durability the market is underwriting in Spotify’s multiple.

The easy part — proving the business could be profitable at all — is done and priced in.

The harder part, sustaining double-digit margin gains against a royalty structure Spotify doesn’t control, is the actual bet investors are making now.

The One Risk Analysts Keep Underweighting

Three risks are worth real attention here, and only one of them gets proportional coverage.

The first, and the one everyone talks about, is competition from Apple, Amazon, and YouTube Music — companies that can subsidize a streaming product with hardware or retail margins Spotify doesn’t have.

It’s real, but Spotify has weathered it for a decade without losing its lead in monthly active users, so I’d argue this risk is already reasonably well understood and priced.

The second is governance, and it’s genuinely underdiscussed.

Founders Daniel Ek and Martin Lorentzon together control 69.3 percent of voting power through a beneficiary-certificate structure, despite owning only around 23 percent of the economic shares.

If the newly installed co-CEO structure — Alex Norström and Gustav Söderström, in the roles since January 2026 — runs into strategic disagreement with outside shareholders, there’s essentially no mechanism for those shareholders to force a change.

This isn’t a near-term catalyst, but it’s a standing feature of the risk profile that gets far less airtime than it deserves relative to its potential impact.

The third, and the one I think matters most financially, is licensing concentration.

Spotify’s entire gross margin story depends on growing revenue faster than royalty costs set largely by three record labels with ”most favored nation” clauses in their contracts.

If any of Universal, Sony, or Warner extracts materially worse terms at the next renewal — and these are multi-year, not automatically renewable agreements — the margin expansion that’s driving this entire investment case could stall or reverse in a way that has nothing to do with subscriber growth or competitive pressure.

The Verdict

I think Spotify has genuinely earned its re-rating from cash-burning growth story to disciplined, profitable platform business — the margin data across six straight quarters is too consistent to dismiss as noise.

But the stock isn’t cheap anymore, and at a forward P/E above 30 times, there’s limited room for anything to go wrong on the licensing side or in Premium ARPU before the multiple starts to look like the problem rather than the opportunity.

What would change my mind in either direction:

• A Q3 2026 print that misses guidance on gross margin as well as subscriber adds — not just one metric — would suggest the expansion is decelerating faster than the market expects.
• Any public signal of tension in the upcoming licensing renewal cycle with Universal, Sony, or Warner would be the single biggest threat to the entire margin thesis.
• Continued ARPU weakness beyond currency effects into 2026 would be the clearest sign that pricing power is softer than the headline numbers suggest.

This is a stock for the investor who wants exposure to a genuine, multi-year platform margin story with a fortress balance sheet behind it — not for anyone looking for a cheap entry point.

If you’re underwriting Spotify here, you’re underwriting continued flawless execution against a licensing structure the company doesn’t fully control, and paying a growth-stock multiple for the privilege.

It manufactured it, patiently, over a decade of semaglutide research that most of the market ignored until Wegovy’s launch turned it into a household name.

That’s the backdrop worth holding onto, because the last eighteen months look, on the surface, like a company falling apart.

The share price is down 48 percent since the end of 2024.

Its most important pipeline asset has now failed to hit its primary target twice. And yet the company just raised its full-year guidance for the second consecutive quarter.

Both things are true at once, and untangling them is the whole game.

Semaglutide, Sold Two Ways

Novo Nordisk’s business is deceptively simple to describe and genuinely hard to replicate: one molecule, semaglutide, sold under different brand names into two related but distinct markets.

Ozempic and Rybelsus treat type 2 diabetes; Wegovy, in injectable and – since January 2026 – pill form, treats obesity.

Both work by mimicking GLP-1, a gut hormone that regulates appetite and blood sugar.

The commercial insight was recognizing, earlier than most competitors, that the same drug class could anchor two enormous and overlapping markets.

What’s easy to miss is how much of the current story runs through distribution, not chemistry.

Wegovy’s oral pill crossed 5 million prescriptions in the US since its January launch and reached roughly 265,000 weekly prescriptions by mid-July — the strongest GLP-1 volume launch the market has seen.

That’s not just a new SKU; it’s a wedge into a self-pay and telehealth channel (NovoCare Pharmacy, plus partnerships with Ro, WeightWatchers, and LifeMD) that operates almost entirely outside the traditional insurance-and-PBM system Novo has spent decades navigating.

It’s a genuinely different go-to-market motion, running in parallel with the legacy insured channel.

The strategic pivot underneath all of this is pricing, not product.

Novo signed a “Most Favoured Nations” agreement with the US administration in late 2025, and starting January 2027 it will cut US list prices on Wegovy and Ozempic by roughly 50 and 35 percent, respectively.

That’s the trade the company is making explicitly: give up price to defend volume and expand access, on the bet that GLP-1 penetration in a market of roughly a billion people living with obesity still has enormous room to run.

The Numbers That Matter

Start with the one that should worry anyone modeling Novo Nordisk off its historical growth rate: adjusted sales grew just 2 percent at constant exchange rates in the first half of 2026.

That’s not a rounding error — it’s a cliff relative to the 25 to 35 percent annual growth the company posted every year from 2022 through 2024.

Reported growth looks far better (18 percent in H1), but that’s almost entirely a function of a one-off DKK 26.8 billion reversal of US rebate provisions booked in the first quarter — strip that out, and the underlying business is barely expanding.

Margin tells a similar story.

Adjusted gross margin fell to 79.3 percent in H1 2026 from 83.1 percent a year earlier, hit by lower realized US prices, roughly DKK 3 billion in one-off manufacturing right-sizing costs, and currency drag.

That’s a nearly four-point compression in two quarters for a company whose margin structure used to be a point of near-total stability.

Then there’s the segment detail that doesn’t show up in the headline figures: Wegovy injectable sales in the US fell 22 percent at constant currency in the second quarter, even as the Wegovy pill grew from nothing.

That’s not simply substitution — a meaningful chunk of that injectable decline is lower realized pricing, which means Novo is trading price for volume inside its own franchise before the 2027 list-price cut has even landed. If that’s happening now, the margin math for 2027 and beyond deserves real scrutiny, not just a guidance-range assumption.

Against that backdrop, the guidance revision looks less impressive than the headline suggests. Novo raised full-year 2026 adjusted sales and operating profit growth guidance from a range of -4 percent to -12 percent (as of May) to 0 percent to -6 percent (as of August) — both in constant currency.

That’s a real improvement, but the starting point was already a guidance cut from the growth rates investors got used to.

The number I watch most closely is that adjusted sales growth figure, because it’s the cleanest read on whether the deceleration from 31 percent (2023) to 6 percent (2025) has actually found a floor, or is still searching for one.

What the Chart Isn’t Telling You About the Growth Story

The five-year sales chart looks, at a glance, like a company still compounding nicely — the bars keep climbing, right through 2025.

That’s true in absolute terms and almost beside the point.

What matters is the second line: growth of 31 percent in 2023, 25 percent in 2024, and just 6 percent in 2025, with the underlying (adjusted) figure for H1 2026 running at only 2 percent.

The share price has already done the work of pricing that deceleration in — it’s why the stock sits near DKK 292 today versus DKK 624 at the end of 2024, a nearly 50 percent drawdown that happened before this week’s earnings reaction even started.

What the chart can’t show is whether 2025’s growth rate is the new cruising altitude or still a plane in descent; that’s a forward-looking question the historical numbers simply can’t answer on their own.

The Market Is Pricing Novo as a Value Stock, Not a Growth Stock — And That’s the Real Story

Here’s what’s actually interesting: the market isn’t debating whether Novo Nordisk is a good business anymore. It’s debating whether it’s still a growth business at all.

At roughly 11 times trailing adjusted earnings, Novo trades closer to how the market prices a mature, ex-growth pharma name than a company still leading the fastest-growing drug category in the industry. Eli Lilly, its closest competitor, trades at nearly four times that multiple.

Three ways to read that gap.

One: the market is right, and Novo’s growth rate really has structurally reset to low single digits, in which case an 11x multiple is arguably fair, maybe even generous given the pipeline risk.

Two: the market is overcorrecting for a string of bad clinical headlines and underpricing a business that still controls the largest obesity franchise on earth.

Three — and this is the version I find most persuasive — the market isn’t mispricing Novo so much as refusing to underwrite CagriSema until it sees real data, and that refusal is entirely rational given the trial history.

The multiple gap isn’t really about Ozempic or Wegovy. It’s a referendum on whether Novo’s next act will work.

The One Risk That Isn’t About Pricing

Everyone talks about US drug pricing when discussing Novo Nordisk, and it’s a legitimate risk — the 2027 list-price cuts of up to 50 percent will compress margin, full stop.

But it’s not the risk that should keep an investor up at night, because it’s known, guided, and already partially reflected in the stock.

The risk that matters more is CagriSema, the combination amylin-GLP-1 drug Novo needs to keep pace with Eli Lilly’s tirzepatide.

It missed non-inferiority against tirzepatide in the REDEFINE 4 head-to-head trial back in February.

Then, on the same day as this quarter’s earnings release, a lower-dose readout from REDEFINE 9 landed with less punch than hoped, contributing to a same-day share price decline.

Two disappointments in six months, on the company’s single most important next-generation asset, is a pattern, not an anomaly.

The second risk worth naming is more unusual: a federal judge in New Jersey recently allowed part of a shareholder lawsuit over CagriSema’s trial communications to proceed, rejecting Novo’s motion to dismiss.

The case centers on whether the company misrepresented how consistent its Phase 3 dosing protocol was with earlier trials.

Regardless of how the litigation resolves, it signals that some investors believe management’s messaging around CagriSema outran the actual data — a reputational risk that compounds the clinical one.

The third: Wegovy injectable’s 22 percent CER sales decline in the US this quarter suggests Novo is already trading price for volume within its own portfolio, before the bigger 2027 price cut even arrives.

If that internal cannibalization dynamic worsens, the 2027 guidance assumptions look optimistic rather than conservative.

The Verdict

I don’t think Novo Nordisk is broken, and I don’t think it’s cheap in any simple sense either — it’s a business the market has correctly repriced for a genuinely slower growth phase, with real optionality attached if the next pipeline generation delivers.

What would change my mind in either direction is specific: a clean, competitive FDA outcome for CagriSema in the second half of 2026 would go a long way toward closing the Lilly valuation gap; a third consecutive disappointment, whether in the FDA review or the REDEFINE 11 readout expected in the first half of 2027, would suggest the market’s skepticism is earned rather than excessive.

Between now and then, I’m watching gross margin trajectory in Q3 as the cleanest read on whether the pricing story is stabilizing or still deteriorating.

This is a stock for the patient GLP-1 believer who can tolerate binary clinical risk and doesn’t need the growth story to work on this year’s timeline — the cash flow and balance sheet buy you time to wait for CagriSema to either prove itself or get replaced by something else in the pipeline.

It’s the wrong stock if you’re underwriting a re-rating on valuation alone: an 11x multiple can go lower, and has, before it goes higher, if the next data readout disappoints again.

The stock has swung between $12.06 and $57.20 over the past year, a range wide enough to make most large-cap investors uncomfortable before they’ve read a single line of the income statement.

Here’s the number that should reframe how you think about this company: transaction margin dollars, the metric Klarna’s own management says it “manages to,” bottomed at a 31 percent margin in the third quarter of 2025 and climbed back to 38 percent by the first quarter of 2026.

That’s not a story about a BNPL (Buy Now Pay Later) app losing its edge.

That’s a story about a lending business absorbing upfront credit provisions on a fast-growing loan book before the interest income from those same loans has had time to accrue.

Whether you believe the recovery is durable or a one-quarter blip is, in my view, the entire debate about this stock right now.

Payments App or Bank — And Why That Distinction Matters

Klarna operates as a licensed digital bank headquartered in Stockholm, listed on the NYSE under the ticker KLAR.

It runs three consumer products stitched onto a two-sided network of merchants and shoppers: Pay in Full (an everyday debit-like product), Pay Later (an interest-free “charge card equivalent” for medium-sized purchases), and Fair Financing, a longer-duration, interest-bearing installment product that runs three to 48 months.

As of Q1 2026, the network spans 1.075 million connected merchants and 119 million active consumers.

The company’s own framing — “spend-centric, not lend-centric” — is worth taking seriously rather than dismissing as investor-relations language.

Pay Later still makes up 77 percent of gross merchandise volume and turns over more than ten times a year, with an average consumer balance of just $124.

That’s a fundamentally different risk profile than a revolving credit card balance averaging roughly $6,900 in the U.S. Klarna re-underwrites essentially every transaction rather than extending an open credit line, and the company points to a through-cycle provision rate of about 0.6 percent across two decades and more than half a trillion dollars originated.

The Business Model, In Plain Terms

Klarna makes money three ways: merchant fees on Pay Later transactions, interest income on Fair Financing loans, and — increasingly — gains on sale from selling receivables to institutional investors through forward-flow agreements.

That third piece matters more than it might sound. In Q1 2026 alone, Klarna offloaded $1.2 billion of Fair Financing receivables and booked a $57 million gain on sale from it.

This is a capital-light growth lever: it moves credit exposure off the balance sheet, accelerates revenue recognition, and frees up capacity to keep originating loans without raising new equity or debt.

The funding side is arguably the more interesting structural story. Ninety percent of Klarna’s funding comes from consumer deposits — $12.3 billion as of the end of Q1 2026 — mostly long-term fixed deposits concentrated in Europe.

That’s a real cost-of-capital advantage over non-bank BNPL competitors that have to fund receivables through securitization or credit facilities.

It also means Klarna’s growth is less exposed to the kind of funding-market stress that can strangle a pure-play lender overnight.

Distribution is expanding on the merchant side almost as fast as the network itself: Stripe and Nexi are live and ramping as default-on payment partners, with JPMorgan Payments and Worldpay both scheduled to go live sometime in 2026.

That’s a meaningful distribution unlock — Klarna doesn’t have to sell merchants one at a time if it’s the default option inside a payment processor’s stack.

Why Transaction Margin Dollars Is the Number That Tells the Real Story

Four metrics matter here, and they don’t all point the same direction if you only look at the headline growth rate.

Revenue grew 44 percent year-over-year to $1.012 billion in Q1 2026 — the fastest quarterly growth rate in the five quarters of data available.

Fair Financing is doing the heavy lifting: interest income rose 56 percent, and the segment’s GMV grew 138 percent year-over-year, now representing 12 percent of total volume.

Transaction Margin Dollars (TMD) is the number I watch most closely, because it’s the one Klarna’s own CFO explicitly frames as the metric the company manages the business to — not revenue, not GMV. TMD hit $389 million in Q1, up 44 percent year-over-year, but the path to get there wasn’t a straight line.

It bottomed at a 31 percent margin in Q3 2025 before recovering to 38 percent in Q1 2026.

That dip and recovery is the clearest evidence of what management calls “deferred value creation” — Fair Financing requires upfront credit provisions on new cohorts before the interest income from those loans has time to compound.

When growth accelerates faster than expected, margins get squeezed first and expand later.

Provision for credit losses ran at 0.55 percent of GMV in Q1 2026, essentially flat year-over-year (0.54 percent in Q1 2025) and down from 0.65 percent in Q4 2025.

That’s the credit-quality reassurance bulls point to — provisioning didn’t spiral even as Fair Financing volume nearly doubled.

Average revenue per active consumer (ARPAC) rose 10 percent year-over-year to $32, evidence that Klarna is squeezing more value out of its existing 119 million users rather than relying purely on new-user growth to carry the top line.

What the Chart Isn’t Telling You About the Margin Recovery

The transaction margin dollar chart looks, at first glance, like a clean recovery story: a dip in Q3 2025, then three straight quarters of acceleration into Q1 2026.

What the line doesn’t show is that this recovery happened at the same time Klarna’s stock fell from a post-IPO high near $57 to a low of $12.06 in March 2026 — a roughly 79 percent peak-to-trough decline.

The operating business and the stock price were, for a stretch, moving in almost opposite directions.

That’s not necessarily irrational; a lot of that decline predates the Q1 2026 beat and likely reflects the market digesting the Q4 2025 guidance miss along with broader fintech multiple compression.

But it does mean the current ~$20 share price already has some of the Q1 recovery priced in, even after a violent round trip.

The Market Has Already Priced In the Easy Comparison

The consensus narrative on Klarna right now is roughly: “the BNPL pioneer that finally turned profitable, trading at a steep discount to Affirm because it’s newer to the public markets and still working out the kinks.”

That’s directionally true, and it’s also the easy read — which is exactly why I’d push on it a little.

Affirm and Klarna posted broadly similar year-over-year growth in their most recent quarters, yet Klarna trades at roughly $7.5 billion versus Affirm’s $24–26 billion, a discount far wider than growth-rate parity alone would explain.

Some of that gap is legitimate: Affirm has posted multiple profitable quarters in a row, while Klarna has posted exactly one.

Some of it is technical — Klarna’s five-month-old public trading history and 2.08 beta make it a harder position to hold through a drawdown for a lot of institutional mandates, regardless of the underlying fundamentals.

But the part of the gap I think is underappreciated is structural: Klarna’s 90 percent deposit-funded balance sheet is a genuine cost-of-capital advantage that neither Affirm nor Afterpay can replicate without becoming a bank themselves.

The market is pricing Klarna like a scrappy fintech still proving itself. The funding model says it’s closer to a bank that happens to look like a fintech at checkout.

The One Risk Analysts Keep Underweighting

The obvious risk list for Klarna is competitive: Affirm has the Shopify relationship, Block has folded Afterpay directly into Cash App’s 59 million monthly active users, and PayPal is pushing its own pay-later product through sheer distribution scale.

Those are real, and worth watching, but they’re also the risks every BNPL earnings call already spends five minutes on.

The risk I’d actually worry about is guidance credibility.

In Q4 2025, Klarna’s own CFO wrote that transaction margin dollars “came in at $372 million, below our $390-400 million guidance,” attributing the miss to banking-service adoption growing faster than expected.

Fair enough — Fair Financing GMV growth genuinely did accelerate to 165 percent year-over-year that quarter, so the explanation is at least consistent with the data.

But then Q1 2026 beat the top end of its own guided range on every metric, including adjusted operating profit, which came in at $68 million against a guided ceiling of $35 million — essentially double.

That’s not a company dialing in its forecasting; that’s a company whose guidance band has been wrong in both directions within two consecutive quarters.

If Q2 2026, due August 18, produces a third data point that’s just as far off in either direction, the market should start discounting Klarna’s forward guidance the way it does with genuinely unpredictable early-stage growth names — which would be a real re-rating risk, not a one-quarter story.

The second risk worth naming: credit provisions in Fair Financing grew 37 percent year-over-year in Q1 2026, slightly outpacing the 41 percent growth in transaction margin dollars before provisions.

It’s a small gap today. If it widens as the loan book scales into a slower macro environment, the margin recovery this article is built around could reverse.

Where I Land

Klarna’s Q1 2026 was, by any reasonable reading, a genuinely good quarter — the kind of broad-based beat that would normally do a lot to rebuild credibility after a guidance miss.

I think the underlying business is more structurally sound than its stock chart suggests: a deposit-funded balance sheet, a re-underwriting model with a two-decade loss-rate track record, and a transaction margin that’s recovering roughly on the trajectory management laid out.

What I’m not willing to do yet is call the guidance miss in Q4 2025 an aberration, because one clean beat afterward doesn’t erase it — it just leaves the sample size at two data points instead of one.

What would change my mind in either direction: a second consecutive beat against Q2 2026 guidance would meaningfully raise my confidence that Q4’s miss was noise rather than signal.

A second miss — especially one accompanied by rising delinquency in the U.S. Fair Financing cohorts — would tell me the margin recovery story in this article was a favorable quarter dressed up as a trend.

Either way, August 18 tells you more about this stock than the last five months of price action did.

This is a stock for the investor comfortable underwriting execution risk on a young public company with a genuinely differentiated funding model — not for anyone who needs a multi-quarter track record before they can trust management’s own numbers.

If Klarna delivers two more clean quarters against its guidance, the valuation gap to Affirm becomes a much harder case to defend.

If it doesn’t, the discount you’re seeing today is the market being right, not early.

Their price targets run from 205 SEK to 305 SEK — a spread of 100 SEK on a stock trading around 263.

That’s not analysts nitpicking a growth rate. That’s a market that genuinely doesn’t know what this company is worth, at the exact moment the company itself is trying to answer that question by splitting in two.

Most quarterly write-ups on SKF right now will tell you the same three things: margins are up, the Automotive business is being spun off, and there’s a new robotics joint venture in China.

All true.

None of it explains why Citi and Nordea can look at the same set of numbers and land 48 SEK apart on where the stock should trade.

A Century-Old Bearing Maker Splitting Itself in Two

SKF has been building bearings, seals, and lubrication systems since 1907, and it still holds the top spot in a global rolling-bearing market worth roughly 500 billion SEK — ahead of Schaeffler, Timken, NSK, NTN, and JTEKT, the five companies that round out the industry’s “big six.”

The business runs through roughly 17,000 distributors worldwide and sits deep inside customers’ equipment design cycles, which is a nicer way of saying switching costs are real: once an engineer specs a bearing into a machine tool or a wind turbine gearbox, ripping it out for a cheaper alternative is expensive and risky.

What’s changed is the corporate structure sitting on top of that business.

SKF is separating its Automotive division — the part that supplies wheel-end and driveline bearings to carmakers — into a standalone company under the working name SKF Vertevo, with Kerstin Enochsson installed as its CEO and a Stockholm listing targeted for the fourth quarter of 2026, subject to board and shareholder approval.

What remains is a tighter Industrial business built around two units: Bearing Solutions, the core franchise, and Specialized Industrial Solutions, which covers aerospace, magnetic bearings, and lubrication systems.

There’s a third, smaller thread worth noting: a July joint venture with China’s Leaderdrive to build precision transmission components for humanoid robot joints.

It’s early — nowhere near material to the numbers yet — but it’s the first concrete signal that SKF sees its precision-engineering know-how extending past traditional industrial equipment.

Why Free Cash Flow Isn’t the Story — Margin Discipline Is

Start with the number that’s been quietly compounding for two years: adjusted operating margin.

It bottomed at 11.1 percent in the fourth quarter of 2024 and has climbed almost every quarter since, hitting 13.9 percent in the second quarter of 2026.

That’s not a one-off pricing win. It’s eight quarters of a trend, and it’s happening while reported (unadjusted) operating margin actually fell to 9.6 percent in the same period — the gap between the two numbers is entirely separation costs and footprint consolidation charges, roughly 1 billion kronor of them in this quarter alone.

Inside that number, Specialized Industrial Solutions is doing the heavy lifting.

Its adjusted margin went from 10.3 percent to 15.2 percent year over year, on 8.3 percent organic growth driven by aerospace and magnetic solutions.

Bearing Solutions, the bigger and more mature unit, actually saw its margin dip slightly, to 19.2 percent from 20.1 percent — management attributes this to support production being run for Automotive ahead of the split, which is a temporary and self-inflicted drag rather than a competitive one.

The number I watch most closely, though, is net working capital as a percentage of trailing twelve-month sales.

It’s risen from 31.6 percent to 36.4 percent over the past year, and it’s the clearest fingerprint the separation is leaving on the balance sheet.

Operating cash flow for the first half of 2026 came in at 1.6 billion SEK, less than half of what it was a year earlier, almost entirely because of this working capital build.

Leverage remains fine — net debt sits at 0.9 times adjusted EBITDA — but this is the line item that tells you the spin-off has real, current costs, not just accounting noise.

What the Chart Isn’t Telling You About the Working Capital Story

The chart above shows net working capital as a percentage of trailing twelve-month sales, by quarter, since the third quarter of 2024.

For five straight quarters, that line barely moves — it sits in a tight band between 30 and 32 percent, the kind of number that wouldn’t earn a second glance in a normal report.

Then, in the first quarter of 2026, it breaks upward, and it keeps climbing into the second quarter, hitting 36.4 percent.

That’s not noise.

That’s a step-change coinciding almost exactly with the operational ramp-up of the Automotive separation, and it’s a cleaner signal than the margin line: this cost is new, it’s recent, and it isn’t slowing down yet.

The Market Has Already Priced In the Easy Part

Here’s what I think the market has right: SKF’s core Industrial business is genuinely better run than it was two years ago, and the stock’s roughly 31 times trailing earnings — a clear premium to a peer group of NTN, Timken, Nolato, and Volvo trading closer to 25 times — reflects that.

Investors have noticed the margin trend and paid up for it.

What the market hasn’t settled is the separation itself. A 100 SEK spread across price targets isn’t analysts disagreeing about next quarter’s organic growth rate — it’s a genuine split of opinion about how SKF Vertevo will be valued once it trades on its own, and about whether the parent company deserves a sum-of-the-parts premium or a conglomerate discount for getting there.

JPMorgan, at 230 SEK, is effectively betting the transition costs more than it’s worth.

UBS and Deutsche Bank, both at 280, are betting the opposite.

Nobody has SKF Vertevo’s actual trading multiple to work with yet, because it doesn’t exist as a listed company.

That’s the variable the market is pricing on guesswork, and it’s the one that will resolve, one way or another, before year-end.

The One Risk That Isn’t About Demand

The obvious risk with any industrial bearing maker is cyclical demand, and SKF has some of that — Automotive’s organic sales fell 1.4 percent in the second quarter, dragged down by weak European volumes.

But that’s not the risk I’d actually lose sleep over, because it’s already visible in the numbers and largely priced.

The first real risk is execution on the Vertevo listing itself.

“Subject to board and shareholder approval” is doing real work in that sentence — if the listing slips into 2027 or gets pulled entirely, the working capital drag continues without the payoff that’s supposed to justify it.

The second is that working capital trend.

If NWC keeps climbing past 36 percent of sales into the third quarter, it stops looking like a one-time separation cost and starts looking like a structural change in how the business converts profit into cash — a much less forgivable problem.

The third is more subtle: SIS’s margin expansion is impressive, but it’s a small segment riding aerospace and magnetics strength.

If that growth cools while Bearing Solutions is still absorbing support-production costs for Automotive, the group margin trend could stall right when the market is watching most closely.

The Verdict

I’d call SKF a hold, not because the operating story is bad — it’s genuinely improving — but because the stock has already been rewarded for the part of the thesis that’s easy to see, while the part that will actually move the needle is still unresolved.

Three things would change my mind:

• A confirmed listing date and structure for SKF Vertevo, ideally with an indicative valuation range attached
• Net working capital stabilizing or reversing in the third-quarter report
• Evidence that SIS’s margin gains are holding even as support production for Automotive winds down

This is a stock for the investor who’s comfortable owning event-driven uncertainty for a specific catalyst — the Vertevo listing — rather than someone looking for a clean industrial compounder to hold and forget.

It’s the wrong fit if you need a settled valuation story today: until the spin-off prices, you’re underwriting two businesses through the multiple of one, and the market’s own analysts can’t agree on what that’s worth.

Same country, same sector, same broad consumer backdrop.

Wildly different stories.

That contrast is the reason to look at Dino Polska right now.

Not because it’s about to be bought — its founder controls just over half the company and shows no sign of wanting to sell — but because the gap between Żabka’s ending and Dino’s current chart tells you something concrete about what the market actually rewards in this sector, and what it’s still waiting to see from Dino before it forgives the stock.

A Retailer Most International Investors Have Never Heard Of

Dino Polska (WSE: DNP) runs roughly 3,100 mid-sized supermarkets across Poland, concentrated in smaller towns and the edges of bigger cities — the geography most large chains have historically underserved.

The company trades on the Warsaw Stock Exchange at around 31.8 zloty, putting its market capitalization near 31 billion zloty. It’s part of the WIG30 and, unlike Żabka, has no takeover speculation attached to it.

Why a Boring Store Format Is the Whole Point

Dino’s model is almost deliberately unglamorous. Every store looks the same: about 400 square meters, roughly 5,000 products, a meat counter supplied by the company’s own processing plant, Agro-Rydzyna, rather than a third-party supplier.

Twelve distribution centers feed the network, and a thirteenth is now under construction in Zawiercie.

The economics work because the format is cheap to replicate. A standardized store with a predictable footprint is a repeatable unit, not a bespoke real-estate project — which is exactly why Dino has been able to grow its store count by 40 percent over three years without loading up on debt to do it.

Net debt sits at roughly 0.1 times EBITDA, a number most retailers would consider a rounding error rather than a leverage ratio.

The growth plan for 2026 is explicit: management has guided to double-digit percentage growth in new store openings and roughly 2.5 billion zloty of capital expenditure, split between continued rollout and logistics capacity — including that new Zawiercie distribution center and a planned 250–300 million zloty investment in reverse vending machines for bottle and can recycling.

None of this is opportunistic. It’s the same playbook Dino has run for years, just at a larger scale.

The Margin Line That’s Quietly Doing All the Work

Start with the number that actually explains the stock’s recent behavior: like-for-like sales growth hit 4.4 percent in the first quarter of 2026, up sharply from just 0.5 percent a year earlier.

That’s a real acceleration in the existing store base, not just new units padding the topline. Total revenue grew 14.8 percent year-on-year in the same quarter, and total store count rose to roughly 3,100.

Here’s where it gets less comfortable.

EBITDA margin has now declined in every recent comparable period I can check: 7.9 percent in FY2024, 7.6 percent in FY2025, and down to 6.7 percent in the first quarter of 2026 versus 7.2 percent a year before.

Management’s own explanation is that this is deliberate — a pricing policy aimed at maximizing volume in a period of outright food deflation in Poland, plus some weather-related cost noise.

That’s a defensible strategy.

It’s also, notably, not yet a proven one: net profit was essentially flat year-on-year in the first quarter despite that mid-teens revenue growth, which is what operating deleverage looks like on a P&L.

The number I watch most closely is that EBITDA margin line, because it’s the one variable standing between “temporary strategic tradeoff” and “structural erosion.”

A retailer that keeps growing revenue while margin keeps compressing isn’t automatically in trouble — but it needs to show the compression stopping within a couple of quarters, or the market will stop giving it the benefit of the doubt.

A Four-Year Low for a Stock That Rarely Moves This Much

The chart tells a blunter story than the fundamentals alone.

Dino traded near 50 zloty earlier this year before a brutal single-session move: shares fell roughly 16 to 18 percent after the FY2025 fourth-quarter numbers landed in late March, missing consensus EBITDA estimates by a wide margin (613.5 million zloty reported against roughly 721 million expected).

That was the trigger, not the whole story — Citi downgraded the stock to Neutral shortly after, and a second leg lower came over the summer when the pace of new store openings was read by some as evidence the growth engine itself was cooling, not just the margin.

The stock now sits near a four-year low, roughly 30 to 32 zloty, having lost close to 40 percent of its value over the past twelve months.

Beta on the name is unusually low — around 0.5 — which tells you this isn’t a stock that normally whipsaws with the broader market. When a low-beta defensive name moves this much, the cause is company-specific, and in this case it clearly is.

The Market Priced In a Broken Growth Story — I’m Not Sure That’s Right

The dominant narrative right now is straightforward: the growth story cracked.

Analysts who once paid up for Dino’s compounding store count are now asking whether that growth is coming at the expense of unit economics, and whether a slower store-opening cadence signals the easy runway is narrowing.

I think that narrative is directionally right but probably overextended on the growth side specifically.

Store openings running at a “teens” percentage clip and a 4.4 percent like-for-like number are not the profile of a company that’s run out of room — they’re the profile of a company still executing its plan while the market repriced its multiple down to something closer to peers.

What the market may be underweighting is the possibility that the margin pressure genuinely is temporary and strategic, tied to a specific deflationary window in Polish food prices rather than a permanent step-down in unit profitability.

If that’s right, the stock is priced for a worse outcome than what’s likely to show up in the next couple of quarters.

The Real Risk Isn’t Deflation, It’s an Unexplained Boardroom Exit

The margin risk is the obvious one, but it’s worth being specific: if EBITDA margin doesn’t stabilize by the third-quarter print, the market will likely conclude the deflationary pricing strategy isn’t working and start modeling structurally lower profitability into the store-growth story — a re-rating that would be far more damaging than the current discount.

Less discussed but worth flagging: Dino’s management board lost two members within a few months of each other in 2026, one of them barely three and a half months after joining.

That’s an unusual amount of turnover for a three-person executive team, and the company hasn’t offered a public explanation.

It may be nothing. It’s also exactly the kind of governance noise that tends to matter more in hindsight than it does in the moment.

The quieter risk is cash flow.

Dino’s free cash flow has been negative in the most capex-heavy quarters of its expansion, funded by strong operating cash generation rather than debt — which is fine as long as growth capex keeps paying off in new store contribution, but it does mean there’s currently no dividend, no buyback, and limited room to disappoint on store economics without the balance-sheet cushion getting tested.

Proven Execution Gets Bought Out, Dino Still Has to Prove It

I don’t think Dino Polska’s growth story is broken.

The store rollout is intact, the balance sheet gives it enormous flexibility, and a 4.4 percent like-for-like number in a deflationary environment is genuinely impressive execution.

What’s missing is proof that the margin compression is the temporary tradeoff management says it is, rather than the start of something more structural.

Three things would change my mind in either direction:

• EBITDA margin stabilizing at or above 7 percent in the next one to two quarters — that would confirm the volume-over-margin strategy is working as intended.
• Store opening pace holding at the guided “teens” percentage for 2026 — a miss here would validate the growth-is-slowing read that’s already partly priced in.
• Clarity on the management board departures — not because I expect a scandal, but because unexplained executive turnover is the kind of thing that should get an explanation, and its absence is a minor but real yellow flag.

This is a stock for the patient compounding investor who can tolerate a bumpy multiple while the margin question resolves itself — someone underwriting Poland’s structural retail consolidation over three-plus years, not the next earnings print.

It’s the wrong stock for anyone who needs a near-term catalyst or capital return: there’s no dividend, no buyback, and no takeover premium coming, given how tightly the founder controls the register. Żabka’s buyers paid up for proven execution near a high.

Dino, for now, is still being asked to prove it.

And yet the single number that moved this stock to an all-time high last month has almost nothing to do with any of that. It’s chip fabs.

Vacuum Technique — the division that makes the pumps semiconductor plants use to create the near-perfect vacuums their manufacturing processes require — posted order growth of 60 percent in the second quarter.

That’s not a typo, and it’s not just a weak comparison base either, though the base helps.

It’s the clearest sign yet that the AI infrastructure buildout has started showing up in the order books of companies most investors would never think to associate with it.

The stock has responded accordingly, and the question worth asking is whether it’s responded too much.

A 150-Year-Old Compressor Maker With a New Growth Engine

Atlas Copco is a Swedish industrial group with a market cap around SEK 995 billion, listed on Nasdaq Stockholm.

It runs four divisions:

• Compressor Technique, the mature cash-generating core (roughly 46 percent of revenue)
• Vacuum Technique, which serves semiconductor and scientific customers (about 22 percent)
• Industrial Technique, precision tools for automakers and electronics makers (around 16 percent)
• Power Technique, portable compressors and generators for construction (about 17 percent)

It’s Vacuum Technique carrying the current story, and carrying most of the stock’s recent move.

How the Installed Base Actually Makes Money

The business model that ties the four divisions together is the installed base.

Atlas Copco doesn’t just sell a compressor and walk away — it sells decades of service contracts, spare parts and upgrades on equipment that’s expensive to switch away from once it’s running a customer’s production line.

Service now makes up roughly 45 percent of Compressor Technique’s revenue and closer to 30 percent in Vacuum Technique, and that recurring tail is a big part of why the group can post 20-percent-plus operating margins even in a down cycle.

Vacuum Technique runs on a similar logic but a different customer base: semiconductor fabs, scientific instrument makers, food packaging lines.

When a fab commits to a vacuum pump supplier, it’s committing to years of service revenue alongside the initial sale.

That’s the part of the business currently in a boom, and it’s why a company most people picture as a maker of steel boxes has quietly become one of the more resilient industrial businesses in Europe.

The Quarter Where Vacuum Technique Flipped Overnight

Second-quarter orders came in at SEK 50.95 billion, up 27 percent year on year and 26 percent organically — a record for the group.

Revenue grew 9 percent to SEK 44.97 billion, with adjusted operating margin climbing to 21.0 percent from 20.4 percent a year earlier.

But look at where that came from.

Vacuum Technique’s operating margin jumped to 21.0 percent from 18.9 percent, on order growth of 59 percent organically, driven by what management called record demand from semiconductor and flat-panel customers.

Compare that to Power Technique, where margin merely held roughly flat at 17.5 percent versus 17.1 percent a year ago, after five straight quarters of decline through the first quarter of this year — a stabilization, not yet a recovery.

Industrial Technique’s margin did jump to 20.0 percent from 17.1 percent, which is genuinely encouraging, but off a smaller revenue base and a weak prior-year comparison.

The quarterly trend inside Vacuum Technique tells the story better than any single quarter can.

The division’s revenue fell year over year in every quarter of 2025 — down 11 percent in Q2, 12 percent in Q3, 11 percent in Q4 — before flipping to plus 17 percent in the second quarter of this year.

That’s not gradual improvement. That’s a segment going from contraction to acceleration in two quarters, and it’s the number I watch most closely, because it’s the cleanest read on whether the semiconductor capex cycle is actually turning or just had one strong quarter.

A Record High Built on One Segment’s Reversal

The stock closed at roughly SEK 178 the day before the July 16 report and has since climbed to just under SEK 204, clearing the previous all-time high set in June 2024 around SEK 206.

That’s a move of nearly 12 percent in ten trading days, on top of a stock that was already up over 30 percent from its 2025 lows before the report even landed.

Multiple sell-side desks raised price targets in the days after the print — Citigroup to SEK 245, SEB to SEK 230, Morgan Stanley to SEK 215 — while Deutsche Bank, more cautious, moved its target to just SEK 181 and kept a hold rating.

That roughly SEK 64 spread between the most bullish and most cautious targets tells you the sell side itself hasn’t agreed on how much of this quarter is durable.

When a stock breaks a two-year-old record high on the back of one segment’s order book, the technical picture isn’t really separate from the fundamental question — it’s the same question, expressed in price.

The Market Has Decided This Is Structural, Not Cyclical

The prevailing read on Atlas Copco right now is straightforward: the semiconductor investment cycle is real and multi-year, Vacuum Technique is the purest way to play it inside a diversified industrial, and the rest of the group provides ballast rather than drag.

I don’t think that’s wrong, exactly. But I think it’s doing more work than the data has earned it yet.

Semiconductor capex has a long history of moving in sharp, unpredictable bursts rather than smooth, structural curves — that’s precisely why Vacuum Technique’s own margin swung nearly nine percentage points over the last two years.

The market is pricing this quarter as the start of a new, durable growth trajectory. It could just as easily be the sharpest quarter of a cycle that mean-reverts the way every semiconductor cycle before it has.

The Concentration Risk No Press Release Will Mention

Three risks are worth sitting with here, and none of them are the ones a press release would flag.

First, concentration. Nearly all of the recent acceleration is coming from one division exposed to one end-market that’s historically been Atlas Copco’s most volatile.

If semiconductor capex intentions cool even modestly heading into 2027 planning season, the group-level growth story loses its main engine overnight, and the stock has priced in continuation.

Second, the currency drag hasn’t gone away. A strong krona shaved 3 percent off Q2 revenue and 8 percent off first-half order growth.

If SEK keeps strengthening, it will keep eating into reported numbers even if underlying demand holds — a headwind that’s easy to overlook when the order growth headline is this loud.

Third, and most overlooked: return on capital employed has fallen for three straight years, from 30 percent in 2023 to 24 percent now, as the capital base grew faster than earnings during the softer 2024–2025 period.

A stock trading at close to 37 times trailing earnings needs that trend to reverse, not just stabilize, to justify the multiple on a forward-looking basis.

Great Business, Fully Priced Quarter

Atlas Copco is a genuinely strong business having a genuinely strong quarter, and I don’t think the semiconductor demand behind it is fake.

What I don’t buy is that the price today still leaves much room for anything other than continued good news. For the thesis to keep working from here, I’d want to see:

• Vacuum Technique orders holding double digits organically into the October report, rather than this quarter proving to be the peak
• Power Technique’s margin actually inflecting upward, not just stabilizing
• Return on capital employed arresting its three-year decline

This is a stock for investors who want quality industrial exposure to the AI infrastructure buildout without owning a pure-play chip supplier, and who are comfortable paying up for that diversification.

It’s the wrong entry point for anyone underwriting a re-rating from here — with the multiple already reflecting a best-case read on one segment, there’s more room for disappointment than for surprise.

If that were the whole story, this would be a short, enthusiastic article.

It isn’t the whole story, and that’s what makes this one worth writing.

Three Sleeves, One Balance Sheet

Investor is Stockholm’s answer to a diversified holding company done at scale: three sleeves of capital, one balance sheet.

The largest sleeve, roughly three-quarters of total assets, sits in listed minority stakes — ABB, Atlas Copco, AstraZeneca, SEB, Saab, and others.

The second, Patricia Industries, is where Investor actually owns and runs things: Mölnlycke, Nova Biomedical, Laborie, Sarnova, Permobil, a cluster of wholly- or majority-owned medtech and mobility companies.

The third and smallest sleeve is a direct bet on EQT — both the listed shares and a slice of its private equity fund family.

Three different risk profiles, three different return drivers, reported once a quarter as a single net asset value per share.

That structure is the whole investment case, and it’s also why a single quarter’s headline number can be misleading.

Adjusted NAV per share rose from 367 kronor at the end of March to 397 kronor at the end of June — an 8 percent jump in three months.

Total shareholder return for the half hit 23 percent, more than double the SIXRX index’s 8 percent. On paper, that’s about as good as a holding company quarter gets.

Dig one layer down and it stops looking like broad-based strength and starts looking like ABB.

The listed portfolio returned 20 percent for the half, and ABB alone contributed nearly 99,000 million kronor of that value increase — more than half the total gain across all thirteen listed names combined.

Atlas Copco, Sobi and Epiroc chipped in real contributions too, but Saab actually lost money for shareholders in the quarter, down 17.5 percent.

This wasn’t a rising tide. It was one very large wave.

Where Investor Actually Makes Money, And Where It Doesn’t

The listed sleeve is straightforward: Investor collects dividends and rides share prices in companies it doesn’t control day-to-day but does sit on the board of.

Patricia Industries is the opposite model — full or majority ownership, active operational involvement, and a portfolio built through both organic investment and acquisition.

Laborie’s January purchase of the JADA system, a postpartum hemorrhage device, cost roughly 3.9 billion kronor and was funded with cash and debt.

Vectura consolidated its remaining 50 percent stake in a Gothenburg health-innovation property complex the same quarter.

This is a holding company that still does deals, not just collects dividends.

And the underlying businesses are doing fine.

Across the nine major Patricia Industries subsidiaries, organic growth in the second quarter came in at 7 percent, with Laborie up 13 percent and BraunAbility up 12 percent.

Adjusted EBITA across the group grew 16 percent. That’s a genuinely strong operating quarter for a portfolio of mid-sized industrial and medtech businesses.

Here’s the disconnect: Patricia Industries’ total return to Investor’s NAV was negative 3 percent for the quarter, despite that growth.

The reason is valuation multiples, not operations. Investor marks these private businesses to market using EV/EBITDA multiples borrowed from comparable listed peers, and those multiples compressed across the board — Sarnova’s estimated value fell by 3.2 billion kronor on multiple contraction alone, Permobil by nearly 2 billion.

Strong businesses, shrinking price tags. That’s a real phenomenon, and it’s the opposite of what happened in the listed sleeve.

Why 14.6x Is The Number I’m Actually Watching

Everyone will look at the 9 percent NAV growth headline.

The number I watch most closely is the 14.6x weighted-average EV/EBITDA multiple Investor applied to its major Patricia Industries subsidiaries at quarter-end — because that multiple, not another strong ABB print, is what would actually re-rate this half of the portfolio.

Right now you have a segment growing organic sales at 7 percent and adjusted EBITA at 16 percent, being valued at a lower multiple than three months ago.

If that multiple simply holds steady next quarter while the growth continues, Patricia Industries’ contribution to NAV should turn meaningfully positive on operations alone — no help needed from the stock market.

If it keeps compressing, growth won’t be enough to offset it, the way it wasn’t this quarter.

The EQT sleeve tells a third story entirely.

EQT’s share price fell hard enough that Investor’s investments in EQT lost 15 percent of their value over the half, with the AB stake down 25 percent in total shareholder return.

Investor kept buying anyway — another 1.7 billion kronor into EQT shares during H1 — which either signals conviction at lower prices or stubbornness, depending on your view of private equity valuations right now.

What The Total-Return Chart Is Actually Telling You

Look past the quarter and the pattern holds across every time horizon Investor discloses: 46.1 percent over one year against 19.1 percent for SIXRX, 17.5 percent annualized over five years against 6.8 percent, and the gap barely narrows even at the twenty-year mark.

This isn’t a lucky quarter compounding into a lucky chart — it’s structural, decades-long outperformance from a business model built on patient, controlling ownership.

The temptation is to read that chart as proof you should own this stock at any price.

I’d read it differently: that record was built by people who bought Investor at a discount to its assets, not at a premium to them.

The chart argues for the strategy. It doesn’t argue for today’s entry price.

What The Market Is Pricing In, And What It’s Missing

The market’s read on Investor right now is straightforward: strong quarter, strong balance sheet, buy the momentum.

What that read glosses over is concentration.

A market that’s rewarding Investor mostly for owning ABB is implicitly betting that ABB’s run continues, because ABB alone now represents 23 percent of Investor’s total assets.

That’s not diversification risk in the abstract — it’s a specific, measurable dependency on a single industrial stock staying hot.

The market is also treating the near-vanishing NAV discount as a non-event, when historically that discount has been the entire reason value investors bothered with holding companies instead of buying the underlying stocks directly.

The Risks Worth Actually Worrying About

First, multiple contraction in Patricia Industries could simply continue.

If EV/EBITDA multiples for medtech and mobility peers keep sliding into next quarter, even double-digit organic growth won’t be enough to move NAV, the way it wasn’t this quarter — and that’s a real, ongoing dynamic, not a one-off.

Second, EQT could keep falling.

A further leg down in EQT’s share price, on top of the 25 percent already lost this half, would turn a currently small drag into a more meaningful one, especially since Investor is actively adding to the position rather than trimming it.

Third, and least likely but not impossible: a sharp reversal in ABB specifically would hit Investor disproportionately hard given how much of this quarter’s gain came from that single name.

It’s not the base case, but it’s the scenario that would expose just how much of the “strong quarter” narrative was really a one-stock story.

Where I Land

Investor remains one of the highest-quality holding companies in Europe — disciplined leverage at 1.9 percent, an AA-/Aa3 credit rating, and a management team that keeps buying good businesses at sensible prices rather than chasing headlines.

None of that is in question. What’s changed is the price you’re being asked to pay for it: a stock trading close to its own net asset value, with the quarter’s gains concentrated in one holding and a private-markets segment that’s currently being valued down despite growing up.

I’d want to see either the discount widen back out or the Patricia Industries multiple stabilize before adding here.

Watch the Q3 report on October 16 for early signs of both.

This is a stock for the patient compounder who’s comfortable owning three different businesses through one ticker and can tolerate a quarter or two of multiple noise in the private portfolio.

It’s the wrong pick if you’re buying because ABB just had a great quarter — that’s a reason to own ABB, not a reason to pay full price for the holding company sitting on top of it.

For eighteen months, Żabka Group traded roughly the way a franchise retailer should – up when store openings and margins beat plan, flat when they didn’t.

Then on July 16, Nikkei reported that Seven & i Holdings, the Japanese parent of 7-Eleven, was in advanced talks to buy a large stake in the company.

The stock jumped almost 11 percent in a single session, kept climbing for the next week, and hit an all-time high of PLN 33.88.

It has now gained about 20 percent in ten trading days on a story that, as of this writing, is still officially just talks – Seven & i’s own statement says plainly that “no decision has been made.”

That gap between what’s confirmed and what’s priced in is the whole story right now.

Poland’s convenience giant, in one paragraph

Żabka Group runs Poland’s largest convenience-store network – roughly 12,750 outlets across Poland and Romania at the end of Q1 2026, almost entirely franchised, complemented by a growing digital ecosystem of meal delivery, eGrocery and unmanned “Nano” stores.

It listed on the Warsaw Stock Exchange in October 2024 in one of the largest Polish IPOs in a decade, backed by private equity firm CVC Capital Partners.

It’s currently worth somewhere around PLN 32–33 billion – up from roughly PLN 22.6 billion in mid-April.

How the money actually works

Żabka doesn’t run most of its own stores – it runs the system that franchisees pay to plug into.

Franchisees get site selection, supply chain, brand, and an increasingly capable digital layer (the Zappka app has around 10 million active users); Żabka takes a cut of sales plus fees, while keeping the capital-heavy real estate and logistics centralized.

That’s why the business scales with relatively modest capex intensity – capex ran at just 5.2 percent of sales to end customers (StEC) in 2025 – and why franchisee churn (7.8 percent, down from 10.5 percent in 2021) is one of the more useful health metrics analysts don’t talk about enough.

The growth engine has three moving parts: new store openings (over 1,300 targeted for 2026), like-for-like sales growth at existing stores, and what Zabka calls New Growth Engines – its Romanian expansion (204 Froo-branded stores, with a long-term target recently raised from 4,000 to 7,600 units) plus its digital businesses, Maczfit, Dietly, Jush! and Delio.

In Q1 2026, network expansion did 64 percent of the growth work, like-for-like did just 25 percent, and NGE did the rest.

That mix matters, and I’ll come back to it.

This is also the exact profile that makes Żabka interesting to a buyer like Seven & i. The Japanese retailer operates something like 86,000–87,000 stores globally but has barely 360 in Europe, confined to the Nordics.

Seven & i has been under pressure from investors since fending off Alimentation Couche-Tard’s takeover attempt, sold its supermarket business to Bain Capital to refocus on convenience, and has explicitly named Europe as a fourth pillar of growth.

Żabka gives it a dense, proven franchise network, a working digital layer, and a management team that’s already built the playbook – without having to build any of it from scratch.

On paper, the strategic logic is clean.

The number I watch most closely

Everyone’s watching the deal headlines. I’m watching like-for-like growth, and it just did something the market seems to be ignoring.

Żabka’s StEC (sales to end customers) growth has been decelerating for three straight years – from around 29 percent in 2022 down to 12 percent year-on-year in Q1 2026.

Some of that is simple math: you can’t compound off a bigger base forever. But the composition of that growth is what matters, and in Q1 2026, like-for-like sales – the purest read on whether existing stores are actually getting busier – grew just 3.2 percent, down from 6.0 percent a year earlier.

Management blames the coldest winter in over a decade and notes that in the warmer weeks of the quarter, like-for-like ran in the mid-to-high single digits, which is a specific, checkable claim rather than a vague excuse.

Here’s the catch: this is the second period in a row weather has been cited as the reason like-for-like undershot guidance. FY2025 also decelerated from 8.3 to 5.3 percent, partly attributed to weather-related headwinds. Once is a data point. Twice is a pattern worth testing – and the test comes on July 30, when Żabka reports H1 2026 results.

If the full first half doesn’t show a real bounce back toward the mid-to-high single-digit range management has guided for, the weather story stops being a sufficient explanation.

Adjusted EBITDA margin, meanwhile, keeps doing exactly what it’s supposed to: 9.1 percent in Q1 2026, up from 9.0 percent a year earlier, with net debt to adjusted EBITDA down to 1.1x from 1.6x.

That deleveraging was healthy enough that Żabka just declared its first-ever dividend – a modest PLN 0.53 per share, a roughly 1.5–2 percent yield at today’s inflated price, paid out July 31.

The chart above shows growth decelerating in a straight line for three years. What it doesn’t show is the last two weeks, where the stock re-rated on M&A speculation that has nothing to do with that trend. Żabka’s fundamentals didn’t change on July 16 – its ownership prospects did.

The market is pricing a deal, not a business

The dominant narrative right now is simple: Seven & i wants in, a deal is close, and the stock should keep re-rating toward global convenience-store multiples.

There’s a real structural argument for that – Żabka has historically traded at a 30–40 percent discount to peers like Alimentation Couche-Tard on EV/EBITDA, and a strategic buyer paying up to build a European platform isn’t an unreasonable scenario.

But the market is skipping a step. Żabka’s two largest shareholders – CVC’s Heket Topco vehicle (around 37.7 percent) and Partners Group’s PG Investment Company (10 percent) – are financial sponsors whose lock-up from a prior share sale expired in May, making them the obvious sellers.

If Seven & i buys enough of that stake to cross 33.33 percent of voting rights, Polish and Luxembourg securities rules could combine to trigger a mandatory tender offer to all remaining shareholders – which is exactly the scenario the market seems to be underwriting.

It’s also exactly the scenario that hasn’t happened yet. Consensus analyst price targets, still clustered around PLN 27, haven’t moved to reflect any of this – not because analysts disagree with the thesis, but because target prices don’t typically get revised on unconfirmed talks.

The risks you should actually worry about

The obvious risk is that talks collapse. Seven & i’s own statement is carefully hedged, and large cross-border retail acquisitions die in due diligence more often than headlines suggest.

If that happens, I’d expect a fast reversion toward the pre-rumor level around PLN 28–29, not a gentle drift – that’s a 10–15 percent air pocket from here with no earnings event required to trigger it.

The second risk is structural, not headline-driven: if like-for-like growth doesn’t recover in H1, the market may eventually have to separate the “Żabka is a great operator” thesis from the “Żabka deserves a re-rating” thesis, and re-price the stock on fundamentals that no longer support today’s multiple even without a deal falling through.

The third is closer to a technicality but matters for anyone buying today specifically for the takeover premium: even if a deal happens, there’s no guarantee it crosses the mandatory-offer threshold.

Seven & i could structure a stake purchase that stays below 33.33 percent of votes, in which case existing minority shareholders may never see the premium currently baked into the share price.

Watch the like-for like and the potential deal closely

I think Żabka is a genuinely good business trading at a price that currently has very little to do with being a genuinely good business.

The operational story – franchise scale, improving margins, deleveraging, a first dividend – is real and intact. But the last 20 percent of the share price move is a bet on a transaction that isn’t signed, at a premium level that isn’t confirmed, with a regulatory trigger that isn’t guaranteed.

For that to keep working, either the deal needs to close at a price above today’s market, or the fundamentals need to catch up to a valuation they haven’t earned yet on their own.

Watch two dates: On Thursday, July 30, when H1 results will show whether like-for-like actually recovers, and whatever comes next from Seven & i or Zabka on deal terms.

This is a position for someone comfortable owning event-driven risk with a defined near-term catalyst – you’re underwriting a specific outcome (deal closes, triggers a mandatory offer, at a premium) rather than a steady compounding story.

It’s the wrong holding if you need your thesis to survive a “no deal” headline without flinching: that single sentence from Seven & i could cost you 10–15 percent before you can react.

Scandic runs 82 hotels there — its second-largest market — and by management’s own estimate, the strike knocked roughly SEK 100 million off top-line revenue, hitting 52 percent of Scandic’s Norwegian hotels versus an estimated 30 percent or less at competitors.

And yet when the strike ended in late May, the company’s Norwegian operating margin had barely moved: 17.6 percent versus 16.4 percent a year earlier, actually up — and Scandic says it gained market share through the disruption.

That’s either a remarkable piece of business-model engineering, or evidence that the real story at Scandic is happening somewhere quieter — in a set of numbers that have been drifting the wrong way for four straight years, unnoticed because none of them individually looks like a crisis.

Nine Countries, One Balance Sheet Nobody’s Worried About

Scandic Hotels Group (SHOT.ST, Nasdaq Stockholm Large Cap) runs 324 hotels and roughly 68,500 rooms across nine countries, mostly in the Nordics.

It trades around SEK 80, a market cap of roughly SEK 17.4 billion, and it just told the market that its underlying profitability shrank for the fourth year running — at the same time as it walked into the largest acquisition in its history.

Sell-side coverage from Jefferies, UBS, Morgan Stanley and DNB Carnegie clusters around a consensus target of SEK 95.6, essentially slightly above where the stock already sits.

Why Scandic Would Rather Not Own Its Hotels

Scandic doesn’t own most of what it operates. It leases the buildings, and critically, the majority of those leases are tied to revenue — rent goes up when the rooms fill, and comes down when they don’t.

That single structural choice is most of the investment case. It’s why the Norwegian strike didn’t show up in the P&L: fewer guests meant less rent owed, not just less revenue earned, and the Norwegian employers’ association compensated the company on top of that.

Three brands cover three price points:

• Scandic (mid-market)
• Scandic Go (economy)
• Signature Collection (premium)

Since November 2025 Scandic has also been running Dalata Hotel Group’s 56 hotels in Ireland and the UK under a management contract, ahead of a formal acquisition expected to close in the second half of 2026.

Scandic is being paid roughly 4 percent of Dalata’s hotel revenue to run someone else’s business before it owns it — a genuinely clever way to have the integration generating cash before it’s generating risk.

The 2030 Plan: 10,000 Rooms, Half Asset-Light

None of this happens in isolation.

In February 2025, Scandic used a Capital Markets Day to lay out a growth plan through 2030: roughly 10,000 new rooms, about half of them under the asset-light Scandic Go brand, plus 30 to 40 new franchise hotels in markets where Scandic currently has no presence.

Franchise expansion is about as close to free optionality as a hotel operator gets — Scandic collects a fee and a brand footprint without leasing a single building.

Layered on top is a partnership with SAS aimed at capturing more of the corporate and loyalty traveler base, plus a new booking platform designed to lift ancillary revenue by selling add-ons like breakfast separately rather than bundling them in.

Management has been explicit that Dalata is a complement to this plan rather than a departure from it — the same goal, a larger and more geographically diversified hotel platform, just accelerated via M&A rather than pure organic build-out.

The capital allocation framework behind all of it is straightforward: fund growth, pay a steady dividend, and use buybacks opportunistically — exactly what a balance sheet carrying almost no net debt is built to support.

The Margin Line Nobody’s Talking About

Here’s the number that matters more than anything in the last two quarterly releases: adjusted EBITDA margin has fallen every year since 2022, from 13.2 percent to 11.7 percent to 11.4 percent to 10.9 percent in 2025 — missing management’s own target of at least 11 percent for the year.

Organic growth told the same story: 3.9 percent against a stated target of at least 5 percent. Both misses, in the same year, from a management team that otherwise executes cleanly.

Contrast that with the balance sheet. Net debt against adjusted EBITDA fell from 1.1x in 2022 to essentially zero — 0.0x — by the end of 2025, and sat at just 0.1x at mid-2026.

That’s an unusually clean capital structure for a hospitality operator heading into a major acquisition, and it’s the reason Scandic could absorb Dalata without touching the dividend.

The fee income from managing Dalata’s hotels ahead of closing added SEK 116 million to adjusted EBITDA in the first half of 2026 alone — a genuinely underappreciated piece of deal structuring that de-risks the largest capital allocation decision in the company’s history before a single euro of purchase price has changed hands.

Break the margin trend down by country and the picture sharpens. Norway (15.7 percent full-year 2025 margin) and Sweden (14.8 percent) are performing well by any standard, and Other Europe, boosted by the Dalata fee income, comes in at 12.8 percent.

Finland is the outlier by a wide margin: 9.8 percent for full-year 2025, and by the first quarter of 2026 the segment had actually gone slightly negative on an adjusted EBITDA basis, before a modest recovery to 5.5 percent in the second quarter.

Three of Scandic’s four markets are performing in line with or ahead of the group average. One of them is dragging the entire consolidated number down.

The number I watch most closely is the trailing-twelve-month adjusted EBITDA margin, because it’s the one line that tells you whether the recent improvement is a real inflection or a seasonal blip inside a longer decline.

Q2 2026 alone came in at 13.3 percent, up from 12.5 percent a year earlier — enough to pull the TTM figure back to 11.1 percent from the 2025 full-year low of 10.9 percent.

Why Q1 Always Looks Ugly — and Why That’s Not the Real Story

Scandic’s business is heavily seasonal, and the gap is larger than most investors probably assume. Q3 — peak summer — carried a 17.1 percent adjusted EBITDA margin in 2025.

Q1 carried 2.2 percent, essentially break-even, weighed down by low business travel, Easter timing and the Christmas and New Year lull that management flags every year as the structurally weakest stretch.

Management also confirms the current growth is overwhelmingly leisure-led, with corporate demand merely stable — a mix that tilts naturally toward the summer quarter.

That means judging the business off any single quarter, or comparing half-year results to full-year results, is close to meaningless without adjusting for which quarters are in the sample.

It’s also why the trailing-twelve-month margin — covering all four seasons exactly once — is the cleanest lens available, and why the chart below is built on that basis rather than calendar-year or half-year snapshots.

Plot the margin from 2022 through the current trailing twelve months and the shape is unambiguous: four years down, then a small uptick.

The uptick is real — Q2 2026’s margin genuinely beat the prior year — but it follows a decline steep enough that one quarter doesn’t undo it.

Why the Street Isn’t Worried — and Where That Might Be Too Comfortable

The dominant narrative around Scandic right now is straightforward: well-capitalized Nordic consolidator, buying growth in Ireland and the UK on favorable terms, funded by a balance sheet that gives it options most hotel operators don’t have.

Analyst sentiment reflects that reading. That’s not a mispriced stock in either direction; it’s a market that’s largely settled on “fine.”

Where I think that comfort gets a little too easy is in treating balance-sheet strength and operating strength as the same thing.

A net debt ratio of 0.0x is genuinely impressive, but it’s also partly a function of restrained capital spending and a buyback program management itself has framed as on hold until the Dalata integration is complete, not a permanent feature.

The market has priced Scandic as if the deleveraging is the operating story.

It’s closer to a precondition for the real test, which is whether Dalata integrates cleanly and whether the margin line actually turns — neither of which is confirmed yet.

Three Things That Would Actually Move the Stock

First, prove the 11-percent margin target is achievable, not aspirational.

Scandic missed its own 2025 targets on both organic growth (3.9 percent against a 5-percent goal) and adjusted EBITDA margin (10.9 percent against 11 percent).

A second consecutive quarter of year-on-year margin improvement — which Q3 2026 would provide, if it happens — would be the first real evidence since 2022 that these targets are within reach rather than restated every year.

Second, land Dalata cleanly.

This is the largest transaction in company history, and management’s own risk disclosure states plainly that the integration “could take longer, be more costly or create more complexity than expected.”

A carve-out that closes on schedule in the second half of 2026, with clearly communicated synergies and a clean first full quarter of consolidated Irish and UK results, would do more for the stock than almost anything else on this list, because it would validate the entire acquisition thesis at once.

Third, stop Finland from being a drag rather than just a weak market. A segment that briefly went negative on adjusted EBITDA in the first quarter of 2026 isn’t merely underperforming — it’s actively subtracting from group profitability while Norway, Sweden and Other Europe all outperform.

Management now points to something more specific than hope: several large meeting and event bookings are already on the books for the second half, the renovation of Scandic’s largest Helsinki hotel finishes at year-end, and the comparison base normalizes after a weak prior-year quarter.

On the back of that, the company is effectively guiding to Finnish margins back above 13 percent in the second half, in line with last year.

That’s a real, checkable number — and given that Scandic already had to walk back one Finland recovery timeline earlier this year, it’s also the one guidance figure in this report I’d hold management to most literally.

None of these are exotic asks. They’re probably the same three things management would list themselves if asked what needs to go right.

I think Scandic is a hold, not a sell, precisely because the balance sheet buys time for all three to play out — but time isn’t the same as certainty, and the stock likely won’t re-rate meaningfully until at least one of them shows up in a quarterly print rather than in guidance.

What I’m watching next is Q3, due November 10.